by Indrani Das  , Robyn Murphy  and Aaron Goldman

Received: 21 July 2022;  Published: 17 July 2023;  doi: 10.21926/rpn.2303012

Celiac disease is a prevalent autoimmune disorder with a rising incidence of 7.5% annually during the second half of the 20th century and the 21st century. Not all genetically susceptible individuals that carry the risk alleles HLA DQ2 and DQ8 go on to develop celiac disease, suggesting that there may be other environmental triggers that contribute to the development of celiac disease in genetically susceptible individuals. Gastroenteritis during infancy has been shown to be associated with increased risk of celiac [...]

by Danilo Donati  , Giacomo Farì  , Federica Giorgi  , Vincenza Amoruso  , Valentina Boetto  , Riccardo Marvulli  , Laura Dell'Anna  , Andrea Bernetti  and Roberto Tedeschi

Received: 31 May 2024;  Published: 10 October 2024;  doi: 10.21926/obm.neurobiol.2404248

This review examines the effectiveness of integrating botulinum toxin type A (BONT-A) with various rehabilitative strategies in treating spastic diplegia in children. The studies analyzed consistently demonstrate significant reductions in spasticity and improvements in gait when BONT-A is combined with interventions such as intensive physical therapy, serial casting, electrical stimulation, physiotherapy, occupational therapy, and robotic-assisted gait training. The findings underscore the importance of personalize [...]

by Úrsula Oswald-Spring

Received: 06 November 2022;  Published: 06 June 2023;  doi: 10.21926/aeer.2302035

The present article studies the policy, numbers, and costs of disaster risk management (DRM) in Mexico, a country highly exposed to climate change, due to two oceans warming up. The PEISOR methodology facilitates interrelating complex interactions and pressures between the natural and the societal system (P), where dangerous effects (E) occur in extreme events, such as floods, landslides, and drought. The impacts (I) of global warming, the pressure of historical poverty, and vulnerable regions were affected by the [...]

by Qiqi Yu  , Kran Suknuntha  , Weixiong Zhong  , Daniel R. Matson  , Aaron S. Hess  and William N. Rose

Received: 13 February 2022;  Published: 02 June 2022;  doi: 10.21926/obm.transplant.2202160

We report a case of thrombotic microangiopathy (TMA) diagnosed in the kidney allograft of a 59-year-old woman who had developed plasmacytoma type monomorphic posttransplant lymphoproliferative disorder (PTLD) 30 years after a simultaneous pancreas and kidney transplant. This report demonstrates a rare etiology of TMA in a kidney allograft occurring in association with PTLD-associated monoclonal gammopathy. The main teaching points are: 1) PTLD may be considered in the work-up of a new TMA in the immunosuppressed po [...]

by Chloe Moran  , Hannah Shaw  , Sue Black  and Kay Brewster

Received: 29 July 2022;  Published: 16 January 2023;  doi: 10.21926/obm.icm.2301006

There is increasing evidence for the effectiveness of brief, group-based compassionate mind training (CMT) in reducing shame and self-criticism, and increasing self-compassion. The current evaluation of an 8-week CMT group programme in an NHS Physical Health Psychology Service supports these findings. Based on a cross-diagnostic sample of 25-39 participants with physical health difficulties, results demonstrate significant reduction in depression and anxiety, significant increase in perceived wellbeing and acceptan [...]

by Luis F. Riquelme  , Sara Diab  , Angela Horyacheva  , Isabel Huribal  , Andreea Shellerud  , Sophia Werden Abrams  and Ashwini M. Namasivayam-MacDonald

Received: 29 April 2022;  Published: 11 August 2022;  doi: 10.21926/obm.icm.2203036

The purpose of this study was to collate and summarize the content covered in published literature describing speech-language pathology management of adult patients with COVID-19 in the acute hospital setting as of February 2022. This review serves as an updated review of the initial recommendations to guide speech-language pathology management for adults with COVID-19 in the acute hospital setting previously provided by Namasivayam-MacDonald and Riquelme in July of 2020. This scoping review followed the Preferred [...]

by Shalika B. Katugaha  , Oksana Shlobin  , Chris King  , Steve Nathan  , Shambu Aryal  , Kareem Ahmad  and Whitney Brown

Received: 04 September 2020;  Published: 13 October 2020;  doi: 10.21926/obm.transplant.2004120

Strongyloides stercoralis infection derived from the donor in solid organ transplant (SOT) places recipients at risk for hyperinfection syndrome and death. We describe the case of a lung transplant recipient who developed strongyloidiasis presenting with GI symptoms and progressing to diffuse alveolar hemorrhage, bacteremia and multi-organ failure. The patient's clinical course illustrates the life cycle of Strongyloides. For treatment, the patient received ivermectin and albendazole. We advocate that early diagnos [...]

by Ahmad R. Alsayed  and Andi Dian Permana

Received: 28 February 2024;  Published: 28 May 2024;  doi: 10.21926/obm.genet.2402237

Bacteriophages, or phages, are viruses that infect bacteria, exhibiting specificity towards particular bacterial strains. Despite being overshadowed by traditional antibiotics in the West, interest in phage therapy has resurged due to the escalating antimicrobial resistance crisis. Understanding phage biology, selection, production, and pharmacology is crucial for their clinical application. Phages interact intricately with the human microbiome, influencing bacterial populations and potentially offering therapeutic [...]

by Jade M Kozuch  , Kamyar Afshar  and Ashley Feist

Received: 15 November 2024;  Published: 20 February 2025;  doi: 10.21926/obm.transplant.2501235

Lung transplant recipients represent a high-risk group for cytomegalovirus (CMV) infection and disease, even among solid organ transplant (SOT) recipients, due to multiple factors. Additionally, CMV has significant consequences in this group including pneumonitis, acute rejection, and chronic lung allograft dysfunction. For the past two plus decades, treatment of CMV in SOT recipients has been limited to off-label use of 4 antiviral medications associated with significant toxicities including myelosuppression and n [...]

by Margaret M Esiri

Received: 27 November 2019;  Published: 04 February 2020;  doi: 10.21926/obm.geriatr.2001103

In this article I wish to put the case for a change of emphasis in the approach to finding a prevention/treatment for Alzheimer’s disease from a focus on beta amyloid to one on tau. In particular, I make the case for aiming to prevent the spread of abnormal tau from the medial temporal lobe to widespread areas of association cortex that are anatomically linked to this critical region. I pose an analogy with cardiovascular disease in which the initiating pathology, lipid streaks, are left untreated until they are so [...]